OrPro Therapeutics, Inc. (San Diego, CA) is developing a therapeutic platform based on thioredoxin, a human protein disulfide-reducing enzyme with unique mucus-normalizing, anti-inflammatory and anti-infective properties. OrPro’s lead candidate Theradux (ORP100) is a new inhaled treatment designed to treat cystic fibrosis (CF) and other obstructive diseases characterized by thickened, stiff and adhesive mucus. The company’s research facilities are located on the Torrey Pines mesa at the 40,000 square foot JLABS facility at Janssen Research & Development’s La Jolla-based West Coast Research Center. JLABS is a “no strings attached” model that provides core research labs hosting specialized capital equipment, shared administrative areas and
individual bench, wet lab and office modules.